The Tumor Risk Score (TRS) - next level risk prediction in head and neck tumor surgery

被引:1
|
作者
Klausing, Anne [1 ]
Waschk, Kristina [2 ]
Far, Frederick [1 ]
Martini, Markus [3 ]
Kramer, Franz-Josef [1 ]
机构
[1] Univ Hosp Bonn, Dept Maxillofacial & Plast Surg, Bonn, Germany
[2] Spital Mannedorf, Dept Internal Med, Mannedorf, Switzerland
[3] Kliniken Mettmann Sud St Josefs Krankenhaus, Dept Maxillofacial & Plast Surg, Hilden, Germany
来源
关键词
Head and neck cancer; Risk prediction; Resource allocation; Intensive care; Risk index; Charlson comorbidity index; MAJOR HEAD; CARE-UNIT; MORBIDITY; CANCER; RECONSTRUCTION; COMPLICATIONS; ADMISSION; OUTCOMES; COSTS; NEED;
D O I
10.1007/s10006-024-01281-8
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Purpose Head and neck cancer surgery often requires postoperative monitoring in an intensive care unit (ICU) or intermediate care unit (IMC). With a variety of different risk scores, it is incumbent upon the investigator to plan a risk-adapted allocation of resources. Tumor surgery in the head and neck region itself offers a wide range of procedures in terms of resection extent and reconstruction methods, which can be stratified only vaguely by a cross-disciplinary score. Facing a variety of different risk scores we aimed to develop a new Tumor Risk Score (TRS) enabling anterograde preoperative risk evaluation, resource allocation and optimization of cost and outcome measurements in tumor surgery of the head and neck. Methods A collective of 547 patients (2010-2021) with intraoral tumors was studied to develop the TRS by grading the preoperative tumor size and location as well as the invasiveness of the planned surgery by means of statistical modeling. Two postoperative complications were defined: (1) prolonged postoperative stay in IMC/ICU and (2) prolonged total length of stay (LOS). Each parameter was analyzed using TRS and all preoperative patient parameters (age, sex, preoperative hemoglobin, body-mass-index, preexisting medical conditions) using predictive modeling design. Established risk scores (Charlson Comorbidity Index (CCI), American Society of Anesthesiologists risk classification (ASA), Functional Comorbidity Index (FCI)) and Patient Clinical Complexity Level (PCCL) were used as benchmarks for model performance of the TRS. Results The TRS is significantly correlated with surgery duration (p < 0.001) and LOS (p = 0.001). With every increase in TRS, LOS rises by 9.3% (95%CI 4.7-13.9; p < 0.001) or 1.9 days (95%CI 1.0-2.8; p < 0.001), respectively. For each increase in TRS, the LOS in IMC/ICU wards increases by 0.33 days (95%CI 0.12-0.54; p = 0.002), and the probability of an overall prolonged IMC/ICU stay increased by 32.3% per TRS class (p < 0.001). Exceeding the planned IMC/ICU LOS, overall LOS increased by 7.7 days (95%CI 5.35-10.08; p < 0.001) and increases the likelihood of also exceeding the upper limit LOS by 70.1% (95%CI 1.02-2.85; p = 0.041). In terms of predictive power of a prolonged IMC/ICU stay, the TRS performs better than previously established risk scores such as ASA or CCI (p = 0.031). Conclusion The lack of a standardized needs assessment can lead to both under- and overutilization of the IMC/ICU and therefore increased costs and losses in total revenue. Our index helps to stratify the risk of a prolonged IMC/ICU stay preoperatively and to adjust resource allocation in major head and neck tumor surgery.
引用
收藏
页码:1547 / 1556
页数:10
相关论文
共 50 条
  • [21] Mutated TP53 in Circulating Tumor DNA as a Risk Level Biomarker in Head and Neck Squamous Cell Carcinoma Patients
    Kampel, Liyona
    Feldstein, Sara
    Tsuriel, Shlomo
    Hannes, Victoria
    Neiderman, Narin N. Carmel
    Horowitz, Gilad
    Warshavsky, Anton
    Leider-Trejo, Leonor
    Hershkovitz, Dov
    Muhanna, Nidal
    BIOMOLECULES, 2023, 13 (09)
  • [22] Limitations of the Hospital Frailty Risk Score in metastatic spinal column tumor surgery Response
    Elsamadicy, Aladine A.
    Koo, Andrew
    Sciubba, Daniel M.
    JOURNAL OF NEUROSURGERY-SPINE, 2023, 38 (03) : 414 - 414
  • [23] ABRIKOSSOFF TUMOR IN HEAD AND NECK
    YOEL, J
    ARAUZ, JC
    TERZIAN, AE
    PRENSA MEDICA ARGENTINA, 1978, 65 (04): : 100 - 105
  • [24] Desmoid tumor of the head and neck
    Wang, Cheng-Ping
    Chang, Yih-Leong
    Ko, Jenq-Yuh
    Cheng, Chia-Hsien
    Yeh, Chun-Fong
    Lou, Pei-Jen
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2006, 28 (11): : 1008 - 1013
  • [25] HEAD AND NECK TUMOR IMMUNOLOGY
    GAZE, MN
    WILSON, JA
    CLINICAL OTOLARYNGOLOGY, 1988, 13 (06): : 495 - 499
  • [26] The thyroid risk score (TRS) for nodules with indeterminate cytology
    Colombo, Carla
    Muzza, Marina
    Pogliaghi, Gabriele
    Palazzo, Sonia
    Vannucchi, Guia
    Vicentini, Leonardo
    Persani, Luca
    Gazzano, Giacomo
    Fugazzola, Laura
    ENDOCRINE-RELATED CANCER, 2021, 28 (04) : 225 - 235
  • [27] Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer
    Brizel, DM
    Schroeder, T
    Scher, RL
    Walenta, S
    Clough, RW
    Dewhirst, MW
    Mueller-Klieser, W
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 51 (02): : 349 - 353
  • [28] MRI during radiotherapy: tumor geometry and changes in organs at risk for head-and-neck patients
    Grundmann, C.
    Kessel, K. A.
    Pigorsch, S.
    Graf, S.
    Nuesslin, F.
    Combs, S. E.
    RADIOTHERAPY AND ONCOLOGY, 2017, 123 : S567 - S568
  • [29] The Tumor Immune Microenvironment Architecture Correlates with Risk of Recurrence in Head and Neck Squamous Cell Carcinoma
    Weed, Donald T.
    Zilio, Serena
    Mcgee, Christie
    Marnissi, Boutheina
    Sargi, Zoukaa
    Franzmann, Elizabeth
    Thomas, Giovana
    Leibowitz, Jason
    Nicolli, Elizabeth
    Arnold, David
    Bicciato, Silvio
    Serafini, Paolo
    CANCER RESEARCH, 2023, 83 (23) : 3886 - 3900
  • [30] Second esophageal neoplasms after head and neck index tumor: Incidence, risk factors and prognosis
    Pujol, Albert
    Llansana, Albert
    Perez-Ugarte, Leyre
    Sauter, Blanca
    Quer, Miquel
    Leon, Xavier
    ACTA OTORRINOLARINGOLOGICA ESPANOLA, 2023, 74 (06): : 339 - 345